Resmed (RSMDF) Cash from Financing Activities (2009 - 2026)

Resmed has reported Cash from Financing Activities for 18 years, with the latest figure at -$255.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 77.16% year-over-year to -$255.2 million; the trailing twelve-month figure through Mar 2026 stood at -$907.8 million (down 8.63% YoY), and the FY2025 full-year result was -$606.3 million, up 45.84% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$255.2 million, up from -$258.3 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $932.9 million in Q4 2022, with the low at -$393.3 million in Q2 2024.
• Historically, Cash from Financing Activities has averaged -$120.6 million across 5 years, with a median of -$163.9 million in 2025.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities surged 527.99% — and 2023, when it slumped 427.99%.
• Resmed's Cash from Financing Activities stood at $932.9 million in 2022, then sank by 125.61% to -$239.0 million in 2023, then jumped by 38.26% to -$147.5 million in 2024, then sank by 75.11% to -$258.3 million in 2025, then grew by 1.2% to -$255.2 million in 2026.
• The last three Cash from Financing Activities figures came in at -$255.2 million (Q1 2026), -$258.3 million (Q4 2025), and -$230.3 million (Q3 2025), per Business Quant data.